Between the Biotech Waves

Today I am talking to Eliot Forster xCEO of F-star Therapeutics.Eliot was at helm of the company as they reversed merged into Springbank Pharmaceuticals & through the recently announced acquisition by Sino Biopharma, a transaction that generated a lot of interest given the very public interactions with CFIUS.Prior to F-star, Eliot was CEO of Immunocore, Creabilis and Solace Pha

Today we have an unusual (& long) podcast where we talk to key members of the Triplet Therapeutics management team. Triplet was founded to develop antisense oligonucleotides targeting the DNA damage response pathway that has been implicated in driving repeat disorders including Huntington's disease - the lead indication for Triplet. The team discusses the challenges in bui

Today we are talking to Tim Yu. Tim is attending physician at the division of genetics and genomics at Boston Children’s Hospital and assoc prof of Pediatrics at Harvard Medical School. The scope of work that Tim does is well beyond what can be covered in this intro however I have gotten to know Tim through his leading the emerging filed of N of 1 plus drugs. Tim worked with Jul

Today we are talking to Barry Greene, CEO of Sage Therapeutics. Barry has had an amazing career spanning over 30 years in the biotech industry. Prior to Sage Barry was President of Alnylam shepherding it with John through its evolution from basic science through commercial product launch. Prior to ALNY Barry was general manager of Oncology at Millennium where he was directly involv

Today we are talking to Joel Marcus. He has shaped the life sciences industry through ARE from the buildings we use to venture and fund investing. His impact can be directly seen in major cities across the US from Boston to NY to San Francisco with over 22million sq ft of space. Beyond Alexandria he is a philanthropist who supports veterans and their families, and through his initi

Today we are talking to Rachel Meyers. Rachel was most recently the CSO of Faze Medicines a company she launched with TRV to focus on the regulation of biomolecular condensates to treat disease. Prior to Faze she was an EIR at TRV prior to which she spent nearly 2 decades at Alnylam. I have had the pleasure of working with Rachel getting an appreciation not only of her as a scienti

Today we are talking to Aofie Brennan, president and CEO of Synlogic. Aoife was trained as a doctor at Trinity College Dublin following which she moved to the US. After completing her postdoctoral research at Beth Israel Aofie joined TolerX focused on developing autoimmune therapies for type I diabetes. Following which Aoife spent 6 years at Biogen ultimately becoming head of Rare

Today we are talking to Drew Weissman. Drew is the Roberts Family Professor in Vaccine Research at Perelman School of Medicine and Director of the Penn Institute for RNA Innovation at the University of Pennsylvania. Drew has spent his career working on RNA biology and vaccine development. He, along with his colleague Katalin Kariko, have been pivotal in the development of mRNA vacc

Today we are talking to Rodolphe Barrangou. Rodolphe is the Todd R Klaenhammer Distinguished Professor at NC State University. He is a scientist entrepreneur who has co-founded a multitude of biotech companies around CRISPR based approaches including CRISPR Biotechnologies, Ancilia Biosciences, TreeCo and Intellia Therapeutics. He is one of the pioneers in CRISPR-Cas9 dating back t

I am delighted to welcome back John Hoffman to Between the Biotech Waves. John is managing director & head of healthcare equity capital markets at Credit Suisse. In mid 2022 John joined the podcast to discuss the market outlook for ’22 and many of his predictions were spot on. It was also one of the most downloaded podcasts of the year. I am welcoming him back to review ’22